133 results about "Hepatic Diseases" patented technology

The invention discloses a polypeptide or a pharmaceutically acceptable salt thereof. The polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or an amino acid sequence in a conservative modification form thereof. The polypeptide or the pharmaceutically acceptable salt thereof disclosed by the invention can be combined with GLP1R and is used for effectively activating the GLP1R. The GLP1R activating polypeptide is obtained through precise calculation and deep learning model optimization, has a short sequence, has unique amino acid arrangement compared with a traditional GLP-1 analogue, can effectively activate a GLP1R receptor, can also be used for treating or preventing metabolic disorder related diseases, and has a good application prospect. For example, obesity, diabetes, dyslipidemia related diseases, fatty liver diseases, metabolic syndromes, non-alcoholic fatty liver diseases and the like.

An application method of a modified peptide derived from Urechis unicinctus is to prepare a drug for treating alcoholic liver disease. The modified peptide derived from Urechis unicinctus is one or more selected from F2-1: IHVKF (SEQ ID NO: 1), F2-2: VHFKI (SEQ ID NO: 2), F4-1: GAWKP (SEQ ID NO: 3), F4-2: AGWKP (SEQ ID NO: 4), F5-1: GTLKP (SEQ ID NO: 5), F5-2: GTPKL (SEQ ID NO: 6), F7-1: IIVRM (SEQ ID NO: 7), and F7-2: IRMVI (SEQ ID NO: 8). The modified peptide derived from Urechis unicinctus can enhance the degradation of alcohol and boost the survival rate of cells with alcoholic liver disease, and also alleviate lipid metabolism and inflammation in mice, protecting liver from alcoholic liver disease. When applied in drug development for treating alcoholic liver disease, the application method offers low-risk, low-cost, and is simple to operate therapeutic options.

The invention relates to the technical field of liver disease prediction, in particular to a metabolism-related fatty liver disease intelligent prediction method and system and a storage medium. The method comprises the following steps: collecting multi-source data, respectively obtaining basic demographic information, laboratory indexes and prediction indexes, and extracting quantitative and qualitative tongue picture parameters; performing variable screening on the tongue picture parameters and the clinical indexes, and determining key prediction variables; obtaining a key variable value according to the key prediction variable, obtaining a prediction result of the occurrence risk of the metabolism-related fatty liver disease, and outputting the prediction result; the system comprises a multi-source data acquisition module, a variable screening module and a prediction result acquisition module. By means of the mode, the intelligent tongue picture parameters and the clinical indexes are fused, and the effect of early prediction of the metabolism-related fatty liver diseases is achieved.

The invention discloses application of a lucid ganoderma extract combined with clostridium butyricum in preparation of fat-reducing food or medicine. The invention finds that the ganoderma lucidum extract is combined with clostridium butyricum for use, so that the weight gain of a mouse induced by high-fat diet can be obviously slowed down, the epididymal fat weight of the high-fat mouse is reduced, and the lipid accumulation in the liver and serum of the mouse is reduced; according to the present invention, with the application of the polypeptide, the fat cell size is reduced, the expression of the key gene mRNA related to lipid metabolism and synthesis in the mouse liver is reduced, the intestinal flora of the mouse is regulated, the obesity can be well improved, and the important application prospect in the preparation of the drugs or food for treating diabetes, reducing blood fat, obesity and non-alcoholic fatty liver disease is provided.

The invention belongs to the technical field of animal model construction, and particularly relates to a non-alcoholic fatty liver disease mouse model based on humanized PNPLA3 I148M transgene as well as a construction method and application thereof, the construction method comprises the following steps: step i: designing CDS of a human gene and a key 3 'UTR element for patent medicine of a small nucleic acid drug in gene plasmid DNA of the constructed model; step ii, using Luc2 or iRFP to report gene expression in the gene plasmid DNA for constructing the model; and (iii) a disease model of the fatty liver disease induced by combining plasmid DNA transient transfer with high-fat diet. The mouse model constructed by the invention has the advantages that a specific exogenous gene expression signal of the liver is detected in real time through small animal living imaging, a human PNPLA3 protein is detected and overexpressed through serum ELISA, PNPLA3 I148M mRNA is detected and overexpressed through liver RT-qPCR, the phenotype of the non-alcoholic fatty liver disease of the liver is determined through 15-week-old pathology, and the whole process of modeling for 8 weeks does not need to be operated in a biosafety secondary laboratory.

The invention provides a mulberry phellinus linteus strain SH08, mulberry phellinus linteus polysaccharide as well as a preparation method and application of the mulberry phellinus linteus polysaccharide, and belongs to the technical field of biological medicines and functional foods. The mulberry phellinus igniarius strain SH08 provided by the invention is preserved in the China Center for Type Culture Collection on October 11, 2025, the preservation address is No. 299, eight road, Wuchang District, Wuhan City, Hubei Province, the strain preservation number is CCTCC NO: M20252203, and the mulberry phellinus igniarius strain SH08 is named as SanghuangAKSQSH01. The invention also provides a method for preparing high-purity mulberry phellinus linteus polysaccharide (SHP-PS) from sporocarp of the strain, and structural characterization of the polysaccharide. Experiments prove that the SHP-PS can effectively improve non-alcoholic fatty liver disease (NAFLD) induced by high fat diet, and the mechanism of the SHP-PS is closely related to blood fat regulation, liver injury and inflammation reduction, intestinal barrier repair, intestinal flora structure regulation and short-chain fatty acid generation promotion. The invention provides high-quality raw materials and a clear technical scheme for developing novel medicines or functional foods for preventing and treating NAFLD, and has important application value.

The application discloses a high-activity UGT1A1 enzyme based on tree shrew and a feed composition for enhancing alcohol metabolism. The catalytic efficiency of the recombinant tree shrew UGT1A1 enzyme on ethanol is significantly higher than that of human isozyme. The core of the application is to provide a complex feed system containing the enzyme, which solves the key bottleneck of poor stability and low delivery efficiency of exogenous enzymes in application through the synergistic effect of enzyme stabilizers, cell penetration enhancers, enteric coatings and coenzyme supply agents. Animal experiments show that the composition can safely and effectively accelerate in vivo alcohol elimination and reduce blood ethanol concentration, and can be used for developing alcoholism products, acute alcoholism treatment drugs and alcoholic liver disease prevention preparations.

The invention discloses a composition for preventing and / or treating alcoholic liver diseases, a product and application thereof. The present invention relates to a composition comprising: breast milk oligosaccharides and vitamins; the breast milk oligosaccharide comprises fucosyllactose and sialic acid lactose; the composition can provide nutritional support for patients with alcoholic liver diseases, repair intestinal mucosal barrier, reduce endotoxin entering blood, improve abundance of beneficial bacteria in intestinal tracts and reduce inflammatory response, so as to achieve the purpose of preventing and / or treating alcoholic liver diseases induced by alcohol.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

The invention relates to the technical field of biological medicines, and discloses application of INHBC as a target spot in prevention and / or treatment of metabolic diseases. Specifically, the invention relates to application of substances for promoting INHBC gene expression or improving protein activity in preparation of products for preventing and / or treating metabolic diseases, and the metabolic diseases comprise diseases caused by energy metabolism disorder, such as obesity, diabetes, fatty liver disease, hyperlipidemia and the like. According to the application disclosed by the invention, liver specific overexpression or INHBC knock-in can improve mouse liver fatty degeneration and abnormal glucose metabolism induced by high fat diet, and in addition, the heat production activity of mouse adipose tissues can be enhanced, so that obesity induced by high fat diet is inhibited; the compound has an important application value in preventing and / or treating metabolic diseases such as obesity, type 2 diabetes and fatty liver diseases.

This invention relates to a composition for improving alcoholic liver damage, belonging to the field of health product technology. This application provides the use of rhodioloside and lactose-N-trisaccharide in the prevention and / or inhibition of alcoholic liver disease. This application also provides a composition of human lactose oligosaccharides and rhodioloside. The compositions described in this application can prevent the occurrence of alcoholic liver disease or inhibit its further deterioration. This application provides a green, safe, and healthy composition, offering an ideal composition for protecting human health.

This invention discloses the application of American ginseng glycoprotein extract in the preparation of drugs for treating alcoholic liver disease, belonging to the field of biomedical technology. This invention verifies that TD can significantly reduce serum ALT, AST, and TG levels in ALD mice, effectively reducing liver damage and lipid accumulation; inhibit NLRP3 protein expression and its downstream targets, effectively alleviating liver inflammation and pyroptosis; and improve intestinal flora imbalance in ALD mice. American ginseng glycoprotein extract has multi-target protective effects against alcoholic liver disease, reducing alcohol-induced liver tissue inflammation and oxidative stress damage. It has a mild composition and high safety profile, and can synergistically exert effects in liver protection, anti-inflammation, and antioxidation, making it suitable for adjunctive intervention and long-term management of alcoholic liver disease, providing a natural, mild, and effective protective pathway for alcoholic liver damage.

The invention belongs to the field of medicine, and particularly relates to application of apium graveolens extract to preparation of medicine for treating fatty liver diseases related to metabolic dysfunction. The celery and sophora flower extract is an alcohol extract of celery seeds and sophora flower buds in a weight ratio of (1: 1)-(4: 1), preferably (3: 1)-(4: 1), and further preferably (3: 1). The invention provides a new choice for clinical medication for treating fatty liver diseases related to metabolic dysfunction, and has great clinical value and social significance.

The invention belongs to the technical field of biology, and discloses application of DVM nanoparticles in preparation of products for treating and / or preventing alcoholic liver diseases, the DVM nanoparticles contain gallic acid derivatives VM and dihydromyricetin; the mass ratio of the gallic acid derivative VM to the dihydromyricetin is 1: 3; in alcohol-induced HepG2 cells, the DVM nanoparticles can better reduce apoptosis of hepatocytes and generation of ROS, improve ADH activity, reduce AST and ALT activities in the cells and improve the hangover alleviating ability in mice, and have a more excellent liver protection effect compared with gallic acid and a positive drug silibinin.

The invention discloses application of a ginseng-keto capsule in treatment of non-alcoholic fatty liver disease, and belongs to the technical field of biological medicine. The tanshinone capsule is used for treating the non-alcoholic fatty liver disease. According to the method, firstly, systematic chemical component analysis is performed on the TSN through an LC-MS / MS technology, and the result shows that the TSN has typical characteristics of multiple components, multiple categories and multiple targets, so that a material basis is laid for playing a multi-link comprehensive intervention role in NAFLD; the essential difference is formed from the existing mechanism research carried out only aiming at a single component (such as dihydrotanshinone I and rosmarinic acid).

This invention belongs to the technical field of natural product active ingredients, specifically relating to a glycopeptide LBGP-I-b derived from wolfberry and its uses. The glycopeptide LBGP-I-b has an average molecular weight of 700–1000 Da, a polypeptide content of 70%–80%, and a polysaccharide content of 10%–20%. The sugar chains are composed of glucose residues, and the sugar chains are linked to the peptide chains via O-glycopeptide bonds. The glycopeptide has functions such as regulating lipid metabolism, lowering blood lipid levels, and improving liver function. The glycopeptide of this invention has a clear source and stable properties, and has good application prospects in the prevention and treatment of metabolic diseases such as metabolic-related fatty liver disease.

The invention provides application of lactobacillus brevicornu and a fermentation composition thereof in hangover alleviating and liver protection, and relates to the technical field of biological fermentation, the lactobacillus brevicornu is lactobacillus brevicornu, the strain number of the lactobacillus brevicornu is KMHD10-222, and the registration number of the lactobacillus brevicornu in the China General Microbiological Culture Collection Center is CGMCC No. 32358. Traditional Chinese medicine substrates can be fermented, and the hangover-alleviating and liver-protecting effects of fermentation products are enhanced. The content of rare ginsenoside, total polysaccharide, total flavone, total phenol, puerarin, daidzein and dihydromyricetin of the lactobacillus brevis KMHD10-222 fermentation substrate extracting solution is increased, the effects of promoting ethanol metabolism and improving the alcoholic liver disease can be improved, and the effects of dispelling the effects of alcohol and protecting the liver are achieved.

The invention provides a small molecule compound A1 which has a good treatment effect on metabolism-related fatty liver diseases. The structural formula of the hydroxyl pyrene compound A1 is shown in the specification. The invention further provides a medicine for preventing and / or treating the metabolism-related fatty liver disease and application of the compound in vivo and in vitro. In-vivo and in-vitro experiments prove that A1 has a remarkable treatment effect on metabolism-related fatty liver diseases. Liver fatty degeneration can be improved, and a definite reversing effect on hepatic fibrosis is achieved. Meanwhile, the compound A1 has better safety, and provides an effective means for preventing and treating the metabolism-related fatty liver diseases.

This invention provides an application of tartary buckwheat antioxidant peptide as a PPARα agonist. The tartary buckwheat antioxidant peptide (SEQ ID NO:1) is used to prepare a PPARα agonist, and this tartary buckwheat antioxidant peptide is used to prepare a drug for improving metabolic dysfunction-related fatty liver disease (MASLD). The tartary buckwheat antioxidant peptide of this invention provides a new drug candidate for improving MASLD and has broad clinical application prospects.

The invention discloses a metabolism-related fatty liver disease single cell data set visualization method and system, and belongs to the technical field of bioinformatics, and the method comprises the following steps: S1, establishing a relational data table including a single cell data set and cell information of single cell data; and S2, visually displaying single cell data analysis results according to the relational data table, wherein the single cell data analysis results comprise a clustering diagram, an expression spectrum, a hypervariant gene point diagram, a volcano diagram, a pathway enrichment diagram and a cell interaction point diagram. Compared with an existing scheme, the method has higher interactivity and supports various interactive operations such as zooming, clicking and suspension. All the graphs call cloud data in real time and render the cloud data in real time based on a user request, and dynamic updating of visual content is ensured. Compared with the prior art, in the prior art, an analysis result is generally made into a static bitmap and then imported into a database, interactive operation cannot be carried out, an image needs to be regenerated once data is updated, and the requirements for real-time performance and flexibility are difficult to meet.

The present invention relates to the use of the Lactobacillus helveticus BGRA43 strain for the prevention and / or treatment of liver diseases and / or liver disorders, preferably metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (N AFLD), and / or for the reduction of liver steatosis. The formulation, preferably for peroral administration, comprising the L. helveticus BGRA43 strain. The formulation comprising the L helveticus BGRA43 strain, which is preferably a probiotic food product intended for human consumption. Lyophilizate of the L helveticus BGRA43 strain, comprising the L. helveticus BGRA43 strain at a concentration from 108 to 1013 CFU / g.

The invention provides application of IDH1 Kcr in diagnosis and treatment of the non-alcoholic fatty liver disease, the research shows that the expression of the IDH1 Kcr level in the non-alcoholic fatty liver disease is reduced, the IDH1 Kcr can be used as a marker for diagnosis and / or prognosis analysis of the non-alcoholic fatty liver disease, diagnosis, early prevention and prognosis prediction of the NAFLD can be realized through the condition of the IDH1 Kcr, and the application of the IDH1 Kcr in diagnosis and treatment of the non-alcoholic fatty liver disease is realized. And an important reference basis is provided for clinical diagnosis and treatment schemes.

The invention discloses a method for promoting conversion of rare ginsenoside in gynostemma pentaphylla and a therapeutic effect of a prepared product on metabolic syndrome. Specifically, the invention discloses a method for promoting conversion of rare ginsenoside in gynostemma pentaphylla, and the method comprises the following steps: (1) taking a proper amount of gynostemma pentaphylla medicinal material dried in the shade, crushing, and adding water for infiltration; (2) soaking for a period of time at a certain water bath temperature; (3) evaporating to dryness, adding ethanol or methanol with a certain concentration, carrying out heating reflux extraction or ultrasonic extraction, cooling an extracting solution, filtering, and carrying out vacuum concentration to obtain a concentrate; and (4) loading the concentrate on macroporous resin, adsorbing, eluting, and collecting the 60-80% ethanol elution part to obtain the total saponins dried in the shade. The method is mild in reaction condition, high in efficiency, high in specificity and free of pollution, and the prepared product is high in rare ginsenoside content and can be used for preventing and / or treating metabolic diseases such as non-alcoholic fatty liver diseases.

The invention discloses a method for analyzing effective components of a compound traditional Chinese medicine formula for treating alcoholic liver diseases, and belongs to the technical field of alcoholic liver diseases. The method comprises the following steps: separating and detecting a compound traditional Chinese medicine formula sample to obtain chromatographic mass spectrometry real-time data of the compound traditional Chinese medicine formula; analyzing and identifying the compound traditional Chinese medicine formula chromatography-mass spectrometry characteristic data according to the compound traditional Chinese medicine formula component analysis and identification model, and determining a compound traditional Chinese medicine formula component analysis and identification result; performing in-vivo tracking on the effective components of the compound traditional Chinese medicine formula, and performing pharmacological activity verification on the analyzed effective components of the compound traditional Chinese medicine formula. The method solves the problem that the effective components of the compound traditional Chinese medicine formula cannot be well analyzed in the prior art, so that the analysis effect of the effective components of the compound traditional Chinese medicine formula is poor. The effective components of the compound traditional Chinese medicine formula for treating the alcoholic liver disease can be well analyzed, and the effective component analysis effect of the compound traditional Chinese medicine formula for treating the alcoholic liver disease can be improved.

The invention discloses a bionic liver chip based on dynamic oscillation and application of the bionic liver chip in fat-reducing functional factor screening, and belongs to the technical field of biomedical engineering and organ chips. The core of the invention lies in that a dynamic bionic liver chip is utilized to construct a controllable and high-repeatability non-alcoholic fatty liver disease (NAFLD) in-vitro model, and a set of systematized fat-reducing functional factor screening and efficiency evaluation platform is established, so that multi-dimensional judgment on the fat-reducing, anti-oxidation and metabolic regulation effects of candidates is realized. The liver chip is simplified in structure, does not need an external perfusion device, is suitable for in-vitro drug screening, natural product function research and mechanism verification, can significantly improve the efficiency, sensitivity and repeatability of fat-reducing functional factor screening, and has wide research and industrial application prospects.

This invention relates to pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease.

This invention discloses a risk prediction device and storage medium for metabolic-associated fatty liver disease in children or adolescents. The two-stage cascaded screening strategy and model of this invention provide a highly accurate, accessible, and scalable solution for the early identification of metabolic-associated fatty liver disease in children or adolescents. This invention utilizes different anthropometric data to identify high-risk groups in routine school physical examinations, followed by further screening using a comprehensive serological index at community health centers, thereby achieving accurate diagnosis of metabolic-associated fatty liver disease and providing clinicians with a non-invasive auxiliary diagnostic tool that combines high precision, high accuracy, and broad accessibility.

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for soothing liver, invigorating spleen and removing fat, a pharmaceutical preparation and a preparation method and application of the traditional Chinese medicine composition. According to the traditional Chinese medicine composition, astragalus membranaceus serves as a monarch drug, scorched hawthorn fruit, semen raphani, perilla stem, ginger processed officinal magnolia bark and selfheal serve as ministerial drugs, and rhizoma pinellinae praeparata, poria cocos, coptis chinensis and mirabilite serve as adjuvant drugs; and finally, salvia miltiorrhiza is used as a conductant drug. All the medicines are combined to play the roles of soothing liver and regulating qi, strengthening spleen and middle warmer, reducing phlegm and burning fat, and relaxing bowel and draining turbidity, so that the traditional Chinese medicine composition has the effect of improving NAFLD, and especially has a better curative effect on the non-alcoholic fatty liver disease caused by internal resistance of phlegm and turbidity.

The invention relates to the technical field of biological medicines, in particular to application of isorhamnetin in preparation of a medicine for preventing and treating fatty liver diseases related to metabolic dysfunction. The invention provides application of isorhamnetin or pharmaceutically acceptable salts, esters or derivatives thereof in preparation of drugs for preventing and treating fatty liver diseases related to metabolic dysfunction. The invention also provides application of isorhamnetin or pharmaceutically acceptable salts, esters or derivatives thereof in preparation of drugs for preventing and treating diseases caused by intestinal flora disorder. The isorhamnetin can recover the diversity and richness of intestinal flora of mice with fatty liver diseases related to metabolic dysfunction and recover the balance of the intestinal flora, and the high-dose (50 mg / kg.d) donor flora transplantation of the isorhamnetin can partially reproduce metabolism improvement. The fatty liver diseases related to obesity or metabolic dysfunction are relieved through an'intestinal flora-bile acid-lipid metabolism 'axis.

The present disclosure relates to aromatic compounds and medical uses thereof, in particular to compounds of general formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 may be selected from different substituents; n is 0, 1 or 2; and X is hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, glyceride, anhydride, phospholipid, carboxamide, phospholipid, or a prodrug thereof; or pharmaceutically acceptable salts, solvates, solvates of the salts, or prodrugs thereof. The present disclosure also relates to pharmaceutical and lipid compositions comprising at least one compound according to the present disclosure, and to the use of such compounds as a medicament or for treatment, in particular for the treatment of diseases associated with metabolic and liver diseases, such as non-alcoholic fatty liver diseases and cholestasis diseases. (I)